Kosj Yamoah MD, PhD

What an incredible day celebrating the ribbon-cutting at the @MoffittNews Speros Outpatient Center. I’m thrilled to showcase our Richard M. Schulze Family Foundation Proton Therapy Center, which will bring highly precise proton therapy to patients and expand access to care!

Meeting the first patient who will receive proton therapy at @MoffittNews in just 10 days was a powerful reminder of why my work matters. Looking forward to beginning treatment and bringing this advanced technology closer to home for our community.

#FollowFriday Meet Santanu Adhikary, PhD (@Santanu_Ads), a postdoctoral researcher studying the molecular biology of breast cancer and therapy-resistant lung adenocarcinoma. His research focuses on metabolic vulnerabilities and noncoding RNA to identify new strategies for overcoming treatment resistance. Follow him for insights into translational research. #MoffittAmbassadors

After more than a decade on Moffitt’s board, Paul Anderson (@PaulAndersonPTB) came to know the cancer center in a new way: as a patient. He shares what two cancer diagnoses taught him about care, compassion and hope. tampabay.com/viewpoints/202…

During the last morning poster session at #ASCO26, Kriti Gera, MD (@kriti_gera_), shares research comparing lymphodepletion strategies before CD19 CAR-T therapy, highlighting findings that suggest a potentially safer approach without compromising efficacy for patients with B-cell acute lymphoblastic leukemia. #MoffittASCO26

While at #ASCO26, Richard Kim, MD, stopped by the #MoffittASCO26 booth to discuss research exploring FGFR2-targeted treatment strategies, from real-world analyses in advanced cholangiocarcinoma to investigational approaches for patients with FGFR2-altered solid tumors, helping advance precision medicine in cancer care. #ASCO26

While at #ASCO26, Ariosto Silva, MD, shares research exploring an AI framework designed to bring together clinical, laboratory and molecular data to support personalized cancer care and accelerate future treatment discoveries. #MoffittASCO26

We caught up with Martine Extermann, MD, PhD, at the Moffitt booth during #ASCO26 to discuss advances in senior oncology research, including ways to help older adults better prepare for and recover from treatment while maintaining their quality of life. #MoffittASCO26

While at #ASCO26, Tiago Biachi, MD, PhD (@BiachiTiago), stopped by the booth to discuss research evaluating an investigational treatment approach for previously untreated, unresectable or metastatic colorectal cancer. #MoffittASCO26

During #ASCO26, Andrew Kuykendall, MD (@KuykendallMd), shares research exploring treatment patterns and overall survival in relapsed or refractory myelofibrosis, highlighting insights from clinical trial and real-world data. #MoffittASCO26

‼️New findings from the SARC041 trial presented at #ASCO26 suggest abemaciclib significantly improved progression-free survival in patients with advanced dedifferentiated liposarcoma, supporting its potential as a new treatment option for this rare sarcoma subtype. Moffitt’s Mihaela Druta, MD (@MihaelaDruta), stopped by the booth to discuss the data from Mark Dickson, MD, of @MSKCancerCenter, highlighting the promise of a new therapy for patients with recurrent or metastatic dedifferentiated liposarcoma. #MoffittASCO26

At the final poster session at #ASCO26, Kamran Ahmed, MD (@KAhmedMD), shares research evaluating brain MRI surveillance in stage IV breast cancer and efforts to better understand brain metastases. #MoffittASCO26

At #ASCO26, Karen Lu, MD (@karenluMD), joins @PatrickHwuMD to discuss Moffitt’s strong presence at the annual meeting and the innovations driving the future of cancer care. From advances in targeted therapies and immunotherapy to leadership in digital pathology and rare cancer diagnosis, they highlight how Moffitt continues to help shape the next generation of oncology breakthroughs. #MoffittASCO26

From #ASCO26, Mihaela Druta, MD (@MihaelaDruta), highlights a study she co-authored evaluating afamitresgene autoleucel (afami-cel), a MAGE-A4-targeted T-cell therapy, in advanced synovial sarcoma. Pooled trial data showed meaningful responses, pointing to the potential of engineered T-cell therapies for patients with this rare and challenging disease. #MoffittASCO26

At #ASCO26, Mihaela Druta, MD (@MihaelaDruta), discusses one of her co-authored studies presented during the antibody-drug conjugate session evaluating mecbotamab vedotin, an AXL-targeting ADC, in heavily pretreated bone sarcomas. Findings demonstrated encouraging overall survival outcomes, highlighting its potential in a patient population with significant unmet need. #MoffittASCO26

While at #ASCO26, Guilherme Rabinowits, MD, stopped by the #MoffittASCO26 booth to discuss findings from his research evaluating FID-007 in combination with cetuximab for recurrent or metastatic head and neck cancer, including encouraging response rates and a manageable safety profile. #ASCO26

From #ASCO26, Nikhil Khushalani, MD (@DrKhushalani), and Vernon Sondak, MD (@VernSondakMD), discuss emerging melanoma research that could help refine treatment strategies and improve quality of life for patients. Highlights include new data on treatment de-escalation for patients with exceptional responses and next-generation TIL approaches designed to maintain efficacy while reducing treatment-related toxicity. #MoffittASCO26

While at #ASCO26, Zeynep Eroglu, MD, stopped by the booth to discuss research exploring adaptive treatment approaches in advanced BRAF V600E-mutant melanoma, using ctDNA, imaging and patient-specific treatment strategies to help guide therapy decisions. #MoffittASCO26